Medchemexpress/SBE-&beta-CD(同义词:磺丁基醚-β-环糊精)/HY-17031/1g

价格
¥1920.00
货号:HY-17031-1g
浏览量:127
品牌:MCE
服务
全国联保
正品保证
正规发票
签订合同
商品描述
SBE-β-CD is a sulfobutylether β-cyclodextrin derivative, it is an excipient or a formulating agent used to increase the solubility of poorly soluble drugs.
Description

SBE-β-CD is a sulfobutylether β-cyclodextrin derivative, it is an excipient or a formulating agent used to increase the solubility of poorly soluble drugs.

In Vitro

SBE-β-CD is a chemically modified β-CD that is a cyclic hydrophilic oligosaccharide which is negatively charged in aqueous media. β-CD functioned is a solubilizer only at low concentrations, whereas SBE7-β-CD exhibits strong solubilizing effects over a wide concentration range[1].

In Vivo

SBE-β-CD is a derivatized form of β-cyclodextrin that has been developed as a safe and effective solubilizing agent for drugs being administered by parenteral and other routes (including oral). SBE-β-CD is a cyclic carbohydrate comprised of seven glucose molecules; the resulting truncated cone-like structure being further derivatized with an average of seven sulfobutyl ether groups[2]. The calorimetric data for the Compound 1/SBE-β-CD complex indicates an extremely strong interaction, with an association constant of 2.3±(0.2)×106M-1 at 25°C and 1.6±(0.2)×106M-1 at 37°C[3]. SBE-β-CD alone evokes a mild cardio-depressant effect independent of cocaine treatment (p=0.0001 compared to baseline) but attenuates further cocaine-induced decreases in RPP, dP/dtmax, and dP/dtmaxabs at high cocaine concentrations. No significant effect is seen on line pressure SBE-β-CD alleviates the most pronounced cardiac depression for RPP, dP/dtmax, and dP/dtmaxabs. This differential effect of SBE-β-CD at low and high concentrations produces an interaction effect in the two-way ANOVA for RPP (p<0.0001), dp/dtmax="" (p="0.0001)," and="">abs (p=0.0015), and prevents any overall treatment effect. Infusing SBE-β-CD also attenuates the cardiac depression associated with cocaethylene toxicity for RPP and dP/dtmax. No differences are observed between ethanol-treated controls and cocaethylene plus SBE-β-CD groups[4].

References
  • [1]. Fukuda M, et al.Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.Int J Pharm. 2008 Feb 28;350(1-2):188-196.

    [2]. Lockwood SF, et al. Improved aqueous solubility of crystalline astaxanthin (3,3"-dihydroxy-beta, beta-carotene-4,4"-dione) by Captisol (sulfobutyl ether beta-cyclodextrin). J Pharm Sci. 2003 Apr;92(4):922-926.

    [3]. Charman SA, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006 Feb;95(2):256-67.

    [4]. Fettiplace MR, et al. Cardiac depression induced by cocaine or cocaethylene is alleviated by lipid emulsion more effectively than by sulfobutylether-β-cyclodextrin. Acad Emerg Med. 2015 May;22(5):508-17.

Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 0.6890 mL 3.4452 mL 6.8904 mL
5 mM 0.1378 mL 0.6890 mL 1.3781 mL
10 mM 0.0689 mL 0.3445 mL 0.6890 mL
Please refer to the solubility information to select the appropriate solvent.
Animal Administration
[3]

SBE-β-CD is prepared in saline[3].

Rat[3]
A 300 g rat is administered with 1 mL of a 0.1 M SBE-β-CD solution containing 5.64 mg of Compound 1, and assuming an extracellular volume of 90 mL, less than 0.1% of the complex would rapidly dissociate due to the initial effects of dilution. This calculation, combined with the changing blood to plasma ratio in the presence of SBE-β-CD, provides a reasonable explanation for the observed differences in the blood and plasma profiles of Compound 1 after intravenous administration in either the cyclodextrin or cyclodextrin-free formulations. After IV administration of the cyclodextrin formulation, Compound 1 would initially be prevented from distributing into erythrocytes thereby resulting in a whole blood to plasma ratio of less than one. Subsequently, clearance of SBE-β-CD from the circulation would lead to changes in the complexation equilibrium such that the unbound fraction of Compound 1 would increase, thereby reestablishing normal blood to plasma partitioning (i.e. in favour of whole blood) and clearance. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
  • [1]. Fukuda M, et al.Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.Int J Pharm. 2008 Feb 28;350(1-2):188-196.

    [2]. Lockwood SF, et al. Improved aqueous solubility of crystalline astaxanthin (3,3"-dihydroxy-beta, beta-carotene-4,4"-dione) by Captisol (sulfobutyl ether beta-cyclodextrin). J Pharm Sci. 2003 Apr;92(4):922-926.

    [3]. Charman SA, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006 Feb;95(2):256-67.

    [4]. Fettiplace MR, et al. Cardiac depression induced by cocaine or cocaethylene is alleviated by lipid emulsion more effectively than by sulfobutylether-β-cyclodextrin. Acad Emerg Med. 2015 May;22(5):508-17.

Molecular Weight

1451.29

Formula

C₅₀H₈₄Na₂O₄₁S₂

CAS No.

182410-00-0

Storage

4°C, protect from light

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

H2O: ≥ 33 mg/mL; DMSO: 5.625 mg/mL

* "<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity: >98.0%

Data Sheet (130 KB) SDS (389 KB)

COA (102 KB)

Handling Instructions (1252 KB)
  • [1]. Fukuda M, et al.Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.Int J Pharm. 2008 Feb 28;350(1-2):188-196.

    [2]. Lockwood SF, et al. Improved aqueous solubility of crystalline astaxanthin (3,3"-dihydroxy-beta, beta-carotene-4,4"-dione) by Captisol (sulfobutyl ether beta-cyclodextrin). J Pharm Sci. 2003 Apr;92(4):922-926.

    [3]. Charman SA, et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J Pharm Sci. 2006 Feb;95(2):256-67.

    [4]. Fettiplace MR, et al. Cardiac depression induced by cocaine or cocaethylene is alleviated by lipid emulsion more effectively than by sulfobutylether-β-cyclodextrin. Acad Emerg Med. 2015 May;22(5):508-17.

About Us 关于我们 MCE (MedChemExpress) 是全球领先的科研化学品和生物活性化合物供应商。MCE 的产品范围覆盖各种抑制剂、激动剂和化合物库。 我们专注于生物活性化合物,拥有多年的发展历程和丰富的行业经验,专业、高效的企业理念铸造了 MCE 在行业的卓越地位。我们的研发团队拥有众多资深的化学家和生物学家,从产品的 HNMR 数据解析到生物活性数据,从客户的询价到产品的售后服务,MCE 拥有着完善的管理体系,从而保证我们的服务更加高效、准确。MCE 为医药行业的发展注入了新的活力,我们是您研发工作中值得信赖的伙伴! Products MCE 致力于为全球客户提供新颖齐全的高品质小分子活性化合物。25000 多种特异性抑制剂、激动剂作用于表观遗传学、PI3K/Akt/mTOR、凋亡、MAPK、Wnt 等 20 个信号通路的 375 个靶点蛋白,覆盖癌症、神经科学、免疫学等热门疾病研究领域。 MCE 的 50 多种活性化合物库,包含 10000 多种具有生物活性的小分子化合物,可用于 高通量筛选 (HTS) 和 高内涵筛选 (HCS),是进行新药筛选和新适应症发现等研究的专业工具。 MCE 拥有众多全球独家化合物,并有专业团队追踪新的制药及生命科学研究进展,能够为您提供新近研究的活性化合物,以满足您的科研需求。 Quality “确保客户拿到的每一个产品的质量” 是 MCE 的核心理念。在客户收到产品时,我们会同时提供结构和纯度的证明文件。每一个谱图、每一份检测报告均由 MCE 的专业分析中心完成。每一个产品的上市都须经过严格的 QA 审批,从而保证产品的高品质和高质量。MCE 的产品也已被全球数万名客户广泛使用并收录于大量专业文献和专利。 Services MCE 的化学团队在多样化的生物活性分子制备合成方面经验丰富,能够提供大规格的专业定制合成服务。同时,我们还为全球众多企业、科研院所构建各种定制型化合物库。 我们的售前和售后技术支持由来自知名药企的科学家为您提供,在 MCE,您能够获得更为专业的服务。